Skip Navigation

DRUG RECORD

 

IPRATROPIUM

OVERVIEW
Ipratropium

 

Introduction

Ipratropium is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis and emphysema.  Ipratropium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

 

Background

Ipratropium (ip" ra troe' pee um) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing bronchial smooth muscle contractions and alleviating bronchospasm in patients with chronic obstructive pulmonary disease (COPD).  Ipratropium has potent activity against muscarinic acetylcholine type 3 (M3) receptors which are found in bronchial smooth muscle.  Its quaternary ammonium structure decreases its ability to cross lipid membranes such as the blood brain barrier.  Ipratropium was approved for use in the United States in 1986 as a respiratory inhalant and indications include maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema.  Ipratropium is available in various formulations generically and under the brand names Atrovent and Combivent for use as an inhalant.  The typical dose in adults is 1 inhalation 3 to 4 times daily.  The common side effects of parasympathetic stimulation (such as dryness of the mouth and eyes, decreased sweating, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety and restlessness) are uncommon in patients treated with ipratropium by inhaler.  Ipratropium use can cause paradoxical bronchospasm.  Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.

 

Hepatotoxicity

Like other anticholinergic agents, ipratropium has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury.  A major reason for its safety may relate to its low systemic absorption when administered by inhaler.

 

References on the safety and potential hepatotoxicity of anticholinergics are given together after the Overview section on Anticholinergic Agents.

 

Drug Class:  Anticholinergic Agents

 

Top of page


 

REPRESENTATIVE TRADE NAMES
Ipratropium – Generic, Atrovent®

 

DRUG CLASS
Anticholinergic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Ipratropium 66985-17-9 C20-H30-Br-N-O3.x-H2-O Ipratropium Chemical Structure

Top of page


OTHER REFERENCE LINKS
Ipratropium
  1. PubMed logoRecent References on Ipratropium

  2. Clinical Trials logoTrials on Ipratropium

Top of page